DNA-content in endometrial carcinoma of tamoxifen-treated breast cancer patients
| Autor: | B. Moberger, Fornander T, Ann-Cathrin Hellström |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Oncology
medicine.medical_specialty business.industry medicine.medical_treatment Obstetrics and Gynecology medicine.disease Malignancy chemistry.chemical_compound Breast cancer chemistry Internal medicine medicine Carcinoma Adenocarcinoma Sarcoma skin and connective tissue diseases business Adjuvant DNA Tamoxifen medicine.drug |
| Zdroj: | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 4(2) |
| ISSN: | 1525-1438 |
| Popis: | DNA measurements and histopathologic evaluation were performed in 17 patients treated with adjuvant tamoxifen for early breast cancer and who developed endometrial carcinoma during or after the tamoxifen therapy. The tumors were exclusively characterized by euploid DNA content except for two cases, one mixed mesodermal sarcoma, a highly malignant and rare tumor, and one adenocarcinoma. Although the use of adjuvant tamoxifen therapy most likely enhances the risk of developing endometrial carcinoma, the beneficial effects of adjuvant breast cancer treatment is of well-known clinical importance. The hazards of giving long-term tamoxifen seem to be low since the endometrial tumors were associated with low-grade malignancy and euploid DNA pattern. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text